The Office of Technology Licensing was established in 1970 to transfer technologies developed at Stanford. Find out more about OTL's history, mission, staff, and statistics.

Login to TechFinder » 

Engineered EGF polypeptides for improved epidermal and epithelial wound healing


Stanford Reference:

06-058


Abstract


When skin is damaged, the body releases EGF into the area. The presence of EGF attracts nearby connective tissue cells called fibroblasts. The EGF then signals the fibroblasts to begin producing collagen in the area of the wound to build the foundation of new skin tissue.

Under normal circumstances, the body can use this process to heal a wound. But in the case of chronic wounds, as they occur in diabetics, the lesions remain open. In the past, EGF was applied directly to a wound, but the approach was not successful because small polypeptides such as EGF only remain in the wound site for several minutes before they are dispersed. This is not enough time to rebuild tissue.

MIT and Stanford inventors have developed EGF variants with significantly increased binding affinity to the EGF receptor so that the residence time of EGF will be remarkably prolonged and the biological effect enhanced.

A mutant EGF that stimulates cell cycle progression can, thus, be used as a wound healing agent by accelerating and improving the rate and extent of healing. Furthermore, EGF mutants can influence cell migration in vitro and in vivo and so aid wound healing.

Applications


  • Treatment of chronic wounds
  • Cosmetic Application

Advantages


  • EGF mutants have about 30 times more receptor-binding affinity than natural EGF

Publications



Related Technologies


  • S11-262: Epidermal growth factor (EGF) mutants for wound healing and tissue engineering (details)


Related Web Links



Innovators & Portfolio



Patent Status



Date Released

 4/1/2013
 

Licensing Contact


Ximena Ares, Licensing Associate
650-724-0960 (Direct)
Login to Request Information

[-] Map/Timeline

87-057 Endothelial Molecules and the Control of Leukocyte Extravasation - MECA-79 and MECA-367
92-045 Novel Endothelial Adhesion Molecule for Monocytes: L11-CD43
92-146 Achieving B-Cell Lymphoma Growth Modulation and Enhanced Tumor Resistance Using Idiotype/Cytokine Conjugates

more technologies

Related Keywords


wound management   wound healing   therapeutic: wound healing   diabetic wounds   chronic wounds   wound care   06-058   peptide biotherapeutics   therapeutic   topical application   therapeutic: proteins   therapeutic: peptides   therapeutic peptide   peptide therapeutics   
 

   

  

Also of Interest...
87-057 Endothelial Molecules and the Control of Leukocyte Extravasation - MECA-79 and MECA-367
92-045 Novel Endothelial Adhesion Molecule for Monocytes: L11-CD43
92-146 Achieving B-Cell Lymphoma Growth Modulation and Enhanced Tumor Resistance Using Idiotype/Cytokine Conjugates

Recently Viewed...
S06-058 Engineered EGF polypeptides for improved epidermal and epithelial wound healing